These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1012 related articles for article (PubMed ID: 30361801)

  • 21. Induced Pluripotent Stem Cell (iPSC)-Derived Lymphocytes for Adoptive Cell Immunotherapy: Recent Advances and Challenges.
    Nianias A; Themeli M
    Curr Hematol Malig Rep; 2019 Aug; 14(4):261-268. PubMed ID: 31243643
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reprogramming natural killer cells for cancer therapy.
    Wang K; Wang L; Wang Y; Xiao L; Wei J; Hu Y; Wang D; Huang H
    Mol Ther; 2024 Sep; 32(9):2835-2855. PubMed ID: 38273655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy.
    Yilmaz A; Cui H; Caligiuri MA; Yu J
    J Hematol Oncol; 2020 Dec; 13(1):168. PubMed ID: 33287875
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Engineering the next generation of CAR-NK immunotherapies.
    Biederstädt A; Rezvani K
    Int J Hematol; 2021 Nov; 114(5):554-571. PubMed ID: 34453686
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic Engineering of Natural Killer Cells for Enhanced Antitumor Function.
    Mantesso S; Geerts D; Spanholtz J; Kučerová L
    Front Immunol; 2020; 11():607131. PubMed ID: 33391277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. When CAR Meets Stem Cells.
    Lee JM
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31013813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Beyond CAR T cells: exploring alternative cell sources for CAR-like cellular therapies.
    Tsiverioti CA; Gottschlich A; Trefny M; Theurich S; Anders HJ; Kroiss M; Kobold S
    Biol Chem; 2024 Jul; 405(7-8):485-515. PubMed ID: 38766710
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-NK cell in cancer immunotherapy; A promising frontier.
    Marofi F; Abdul-Rasheed OF; Rahman HS; Budi HS; Jalil AT; Yumashev AV; Hassanzadeh A; Yazdanifar M; Motavalli R; Chartrand MS; Ahmadi M; Cid-Arreguid A; Jarahian M
    Cancer Sci; 2021 Sep; 112(9):3427-3436. PubMed ID: 34050690
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetically Engineered Natural Killer Cells as a Means for Adoptive Tumor Immunotherapy.
    Michen S; Temme A
    Crit Rev Immunol; 2016; 36(4):329-347. PubMed ID: 28322137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Inhibition-Resistant CARs for NK Cell Cancer Immunotherapy.
    Zhuang X; Long EO
    Trends Immunol; 2019 Dec; 40(12):1078-1081. PubMed ID: 31732285
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chimeric antigen receptor engineered innate immune cells in cancer immunotherapy.
    Lin C; Zhang J
    Sci China Life Sci; 2019 May; 62(5):633-639. PubMed ID: 30796720
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reprogramming Immune Cells for Enhanced Cancer Immunotherapy: Targets and Strategies.
    Dong Y; Wan Z; Gao X; Yang G; Liu L
    Front Immunol; 2021; 12():609762. PubMed ID: 33968014
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advances in off-the-shelf CAR T-cell therapy.
    Benjamin R
    Clin Adv Hematol Oncol; 2019 Mar; 17(3):155-157. PubMed ID: 30969953
    [No Abstract]   [Full Text] [Related]  

  • 34. Generating universal chimeric antigen receptor expressing cell products from induced pluripotent stem cells: beyond the autologous CAR-T cells.
    Deng X; Zhou J; Cao Y
    Chin Med J (Engl); 2023 Jan; 136(2):127-137. PubMed ID: 36806264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Engineering NK Cells for CAR Therapy-Recent Advances in Gene Transfer Methodology.
    Schmidt P; Raftery MJ; Pecher G
    Front Immunol; 2020; 11():611163. PubMed ID: 33488617
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation of "Off-the-Shelf" Natural Killer Cells from Peripheral Blood Cell-Derived Induced Pluripotent Stem Cells.
    Zeng J; Tang SY; Toh LL; Wang S
    Stem Cell Reports; 2017 Dec; 9(6):1796-1812. PubMed ID: 29173894
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Generation and Functional Characterization of Anti-CD19 Chimeric Antigen Receptor-Natural Killer Cells from Human Induced Pluripotent Stem Cells.
    Klaihmon P; Kang X; Issaragrisil S; Luanpitpong S
    Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 'Off-the-shelf' immunotherapy with iPSC-derived rejuvenated cytotoxic T lymphocytes.
    Ando M; Nakauchi H
    Exp Hematol; 2017 Mar; 47():2-12. PubMed ID: 27826124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CAR-NK cells from engineered pluripotent stem cells: Off-the-shelf therapeutics for all patients.
    Lu SJ; Feng Q
    Stem Cells Transl Med; 2021 Nov; 10 Suppl 2(Suppl 2):S10-S17. PubMed ID: 34724715
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pluripotent stem cell-derived CAR-macrophage cells with antigen-dependent anti-cancer cell functions.
    Zhang L; Tian L; Dai X; Yu H; Wang J; Lei A; Zhu M; Xu J; Zhao W; Zhu Y; Sun Z; Zhang H; Hu Y; Wang Y; Xu Y; Church GM; Huang H; Weng Q; Zhang J
    J Hematol Oncol; 2020 Nov; 13(1):153. PubMed ID: 33176869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 51.